Exploring Multidimensional Risk Factors Associated with Local Adverse Reactions to Subcutaneous Immunoglobulin Therapy: Insights from a Nationwide Multicenter Study

<b>Background/Objectives</b>: Subcutaneous immunoglobulin (SCIg) is a well-established alternative to intravenous immunoglobulin (IVIg) in patients with primary (PID) and secondary immunodeficiency (SID), with demonstrated benefits in safety and quality of life. However, its implementation remains l...

Повний опис

Збережено в:

Бібліографічні деталі
Автори:	Sandra Martínez Mercader, Victor Garcia-Bustos, Pedro Moral Moral, Carmen Martínez Buenaventura, Elisa Escudero Vergara, María Carmen Montaner Bosch, Héctor Balastegui-Martín, Sonia Galindo Maycas, Miriam González Amores, Noemí Gimenez Sanz, Marian Escobar Palazón, María Moreno Mulet, Ignacio Campanero Carrasco, Alicia López, Carlos Daniel Hernández Ruiz, Laura Ruiz-López, Rocío Guzmán Guzmán, Marta Dafne Cabañero-Navalon
Формат:	Artigo
Мова:	Inglês
Опубліковано:	MDPI AG 2025-08-01
Серія:	Biomedicines
Предмети:	common variable immunodeficiency (CVID) immunoglobulin replacement therapy (IgRT) subcutaneous immunoglobulin (SCIg) intravenous immunoglobulin (IVIg) real-world evidence
Онлайн доступ:	https://www.mdpi.com/2227-9059/13/8/1991
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Exploring Multidimensional Risk Factors Associated with Local Adverse Reactions to Subcutaneous Immunoglobulin Therapy: Insights from a Nationwide Multicenter Study

Схожі ресурси